Form 8-K - Current report

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: November 29, 2024

 

AGAPE ATP CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada		001-41835		36-4838886
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

 

1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia,

Taman Desa, Kuala Lumpur, Malaysia 58100

(Address of principal executive offices) (Zip Code)

 

+(60) 192230099

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ATPC		NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On November 25, 2024, Agape ATP Corporation (the “Company”) entered into three Memorandums of Understanding (“MOUs”) with three health institutions in Indonesia, which include Dr. Sardjito General Hospital in Yogyakarta, Dr. H. A. Rotinsulu Lung Hospital in Bandung, and Dr. M. Goenawan Partowidigdo Respiratory Hospital in Bogor (collectively referred as the “Healthcare Institutions”), pursuant to which the Company and the Healthcare Institutions will collaborate on enhancing research capabilities, fostering medical innovations, and conducting clinical studies on the Company’s existing health products.

 

On November 29, 2024, the Company issued a press release (the “Press Release”) announcing the MOUs. The Press Release and a copy of each MOU is furnished as Exhibit 99.1, 99.2, 99.3 and 99.4, respectively to this Current Report on Form 8-K and incorporated herein by reference.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release, dated November 29, 2024
99.2		Memorandum of Understanding between Company and Dr. Sardjito General Hospital
99.3		Memorandum of Understanding between Company and Dr. H. A. Rotinsulu Lung Hospital
99.4		Memorandum of Understanding between Company and Dr. M. Goenawan Partowidigdo Respiratory Hospital
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	AGAPE ATP CORPORATION
Date: November 29, 2024	By:	/s/ How Kok Choong
	Name:	How Kok Choong
	Title:	Chief Executive Officer, President, Director, Secretary and Treasurer (Principal Executive Officer)

 

3

 

Exhibit 99.1

 

 

 

ATPC Expands Global Market Footprint to Spearhead Medical Innovation with MoUs in Indonesia

Agreements to drive clinical research, enhance product safety, and combat respiratory diseases

 

 

 

KUALA LUMPUR, 29 NOVEMBER 2024 – NASDAQ-listed AGAPE ATP Corporation (“ATPC”), today announced the signing of three Memorandums of Understanding (“MOUs”) with prominent healthcare institutions in Indonesia. This initiative aims to advance medical research, introduce innovative treatment strategies and strengthen training programs to address respiratory diseases such as tuberculosis (TB) and chronic obstructive pulmonary disease (COPD). The signing marks a key milestone in ATPC’s strategic expansion plans in Indonesia and Southeast Asia.

 

(L-R): Dr. Fernando Cortizo, ED, Prof. Dr. John Vong, Deputy Chairman and Prof. Dato’ Sri Dr. How Kok Choong, Founder and Group CEO of ATPC; Dr. Sunarto M.Kes, Director of Health Service Governance, Indonesian Ministry of Health; Dr. Khadirin, S.I.P., MARS, Director of Planning and Strategic Service Development, Sardjito General Hospital and Dr. P.R. Widhi Astana, M.Biomed, UPF Yankestrad RS Sardjito Tawangmangu Karanganyar.	(L-R): Dr. Fernando Cortizo, ED, Prof. Dr. John Vong, Deputy Chairman, Prof. Dato’ Sri Dr. How Kok Choong, Founder and Group CEO of ATPC; Dr. Sunarto M.Kes, Director of Health Service Governance, Indonesian Ministry of Health; Dr. drg. Tri Fajari Agustini, Director and Dr. Andi Basuki Prima Birawa, Sp.S., MARS, Director of Human Resources Development of Rotinsulu Lung Hospital.	(L-R): Dr. Fernando Cortizo, ED; Prof. Dr. John Vong, Deputy Chairman; Prof. Dato’ Sri Dr. How Kok Choong, Founder and Group CEO of ATPC; Dr. Sunarto M.Kes, Director of Health Service Governance, Indonesian Ministry of Health; Dr. Ida Bagus Sila Wiveka, Director and Abdul Rozak, SH, Manager of Legal and Public Relations of Goenawan Partowidigdo Respiratory Hospital.

 

The MoUs were signed with Dr. Sardjito General Hospital in Yogyakarta, Dr. H. A. Rotinsulu Lung Hospital in Bandung, and Dr. M. Goenawan Partowidigdo Respiratory Hospital in Bogor. These partnerships focus on enhancing research capabilities, fostering medical innovations, and conducting clinical studies on ATPC’s existing health products. These studies ensure the products comply with Indonesian health standards for safe consumption and use, meeting regulatory requirements prior to market distribution of ATPC’s products.

 

Through these partnerships, ATPC reaffirms its commitment to maintaining the highest standards of safety and efficacy for its health products, further solidifying its position as a trusted innovator in the healthcare industry.

 

The collaborations are built on a shared vision to address critical global health challenges. Together, the parties aim to foster interdisciplinary collaboration, knowledge exchange, and sustainable health practices. Key initiatives include advanced medical research, healthcare professional training, and the introduction of innovative approaches to combat respiratory diseases. The partnerships also aim to connect with international universities and specialist hospitals to further elevate healthcare standards.

 

Page 1 of 3

 

Prof Dato’ Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC said, “TB and COPD remain major public health concerns in both Indonesia and Malaysia. Indonesia ranks among the countries with the highest TB burden globally, with hundreds of thousands of new cases reported annually. Meanwhile, COPD, often linked to high rates of smoking and air pollution, significantly contributes to illness and mortality in both nations. These diseases place immense strain on healthcare systems, highlighting the urgent need for collaborative efforts to improve prevention, diagnosis, and treatment strategies.”

 

Prof. Dato’ Sri Dr How Kok Choong, Founder and Global Group CEO of ATPC (link)

“Our partnerships reflect ATPC’s unwavering commitment to leveraging global expertise and advancing healthcare innovation. By conducting rigorous clinical studies and aligning with Indonesia’s Ministry of Health standards, we aim to ensure that products and services like DSY Wellness, ATP2 and LEGA effectively meet the needs of patients battling respiratory diseases. This marks a pivotal step toward creating a healthier, more sustainable future. We look forward to exploring new collaborations that will further enhance our contributions to Southeast Asia’s healthcare ecosystem.”

 

These partnerships also emphasize the integration of sustainable medical innovations, aiming to enhance long-term well-being and align with the United Nations Sustainable Development Goals (“UNSDG”). Through these collaborations, ATPC reinforces its role as a global leader in wellness and healthcare, advancing scientific research and sustainable health outcomes.

 

The MoU signing ceremony was graced by distinguished guests from the Indonesian Ministry of Health, including Dr. Suranto M.Kes, Director of Health Service Governance, and Prof. Dr. Taruna Ikrar, Head of the Food and Drug Supervisory Authority (BPOM), an agency under the Ministry of Health. Also present were representatives from ATPC, including Prof. Dato’ Sri Dr. How Kok Choong, Founder and Group CEO; Dr. John Vong, Deputy Chairman; and Dr. Fernando Cortizo, Executive Director.

 

###

 

 

 

About AGAPE ATP Corporation

 

Agape ATP Corporation (ATPC) is dedicated to enhancing the quality of life and promoting sustainable development. With a strong foundation built on two core business pillars, ATPC specialises in the provision of health and wellness products that caters to the diverse needs of its customers, ensuring their well-being and vitality. Additionally, APTC delivers comprehensive energy-saving solutions that empower companies to drive sustainability initiatives, reduce energy consumption, and achieve their sustainability goals.

 

For more information, visit www.agapeatpgroup.com.

 

 

 

Issued By: Koa International Sdn. Bhd. on behalf of Agape ATP Corporation

 

For more information, please contact:

 

Jazzmin Wan

Tel: [phone]

Email: [e-mail]

 

Mandy Tan

Tel: [phone]

Email: [e-mail]

 

Page 2 of 3

 

FORWARD-LOOKING STATEMENT

 

Certain statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected benefits and outcomes of the partnerships announced by AGAPE ATP Corporation (“ATPC”) and the potential for medical innovations and healthcare advancements through these collaborations. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to execute its strategies, manage growth, and maintain its corporate culture; the Company’s future business development, financial conditions, and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Malaysia and the international markets the Company plans to serve, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and AGAPE ATP Corporation specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

 

Page 3 of 3

 

Exhibit 99.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 99.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 99.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cover	Nov. 29, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 29, 2024
Entity File Number	001-41835
Entity Registrant Name	AGAPE ATP CORPORATION
Entity Central Index Key	0001713210
Entity Tax Identification Number	36-4838886
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1705 – 1708, Level 17, Tower 2, Faber Towers
Entity Address, Address Line Two	Jalan Desa Bahagia
Entity Address, Address Line Three	Taman Desa
Entity Address, City or Town	Kuala Lumpur
Entity Address, Country	MY
Entity Address, Postal Zip Code	58100
City Area Code	+(60)
Local Phone Number	192230099
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ATPC
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

---